Clinical Trial

Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

Study acronym: GRIT-PKP2
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
The primary objective of this Phase 1/2 long-term follow-up (LTFU) study is to assess the long-term safety and tolerability of LX2020 for the treatment of arrhythmogenic cardiomyopathy (ACM) due to a plakophilin-2 gene (PKP2) pathogenic variant (PKP2-ACM).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-24.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-11-10
Trial Details
NCT Number NCT07050160
Lead Sponsor Lexeo Therapeutics
Conditions Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Enrollment 10 participants
Start Date 2025-08-29
Primary Completion 2030-08 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2025-11-12